journal
https://read.qxmd.com/read/37739888/a-brighton-collaboration-standardized-template-with-key-considerations-for-a-benefit-risk-assessment-for-the-novavax-covid-19-vaccine-nvx-cov2373-a-recombinant-spike-protein-vaccine-with-matrix-m-adjuvant-to-prevent-disease-caused-by-sars-cov-2-viruses
#1
JOURNAL ARTICLE
Bethanie Wilkinson, Kinjal S Patel, Katherine Smith, Robert Walker, Chengbin Wang, Ann M Greene, Gale Smith, Emily R Smith, Marc Gurwith, Robert T Chen
Novavax, a global vaccine company, began evaluating NVX-CoV2373 in human studies in May 2020 and the pivotal placebo-controlled phase 3 studies started in November 2020; five clinical studies provided adult and adolescent clinical data for over 31,000 participants who were administered NVX-CoV2373. This extensive data has demonstrated a well-tolerated response to NVX-CoV2373 and high vaccine efficacy against mild, moderate, or severe COVID-19 using a two-dose series (Dunkle et al., 2022) [1], (Heath et al., 2021) [2], (Keech et al...
September 20, 2023: Vaccine
https://read.qxmd.com/read/37739887/the-role-of-tissue-resident-memory-cd4-t-cells-in-salmonella-infection-implications-for-future-vaccines
#2
REVIEW
Claire E Depew, Stephen J McSorley
Salmonella infections cause a wide range of intestinal and systemic disease that affects global human health. While some vaccines are available, they do not mitigate the impact of Salmonella on endemic areas. Research using Salmonella mouse models has revealed the important role of CD4 T cells and antibody in the development of protective immunity against Salmonella infection. Recent work points to a critical role for hepatic tissue-resident memory lymphocytes in naturally acquired immunity to systemic infection...
September 20, 2023: Vaccine
https://read.qxmd.com/read/37739886/hybrid-large-hepatitis-b-surface-protein-composed-of-two-viral-genotypes-c-and-d-induces-strongly-cross-neutralizing-antibodies
#3
JOURNAL ARTICLE
Takahiro Sanada, Yasunori Oda, Chinatsu Ohashi, Kentaro Isotani, Yasumasa Goh, Michinori Kohara
Hepatitis B virus (HBV) vaccination is known to effectively decrease the risk of HBV infection. However, several issues need to be addressed in order to develop an improved HBV vaccine. Although the HBV vaccine has been shown to be effective, this vaccine needs to be more efficacious in defined groups, including non-responders (i.e., individuals who do not develop a protective response even after vaccination) and in health care workers and travelers who require rapid protection. Furthermore, it has been reported that universal HBV vaccination has accelerated the appearance of vaccine-escape mutants resulting from the accumulation of mutations altering the "a" determinant of the hepatitis B surface (HBs) protein...
September 20, 2023: Vaccine
https://read.qxmd.com/read/37735055/review-factors-influencing-parents-decisions-to-vaccinate-children-against-covid-19
#4
REVIEW
Haifa S Alharbi
INTRODUCTION: Vaccination is a cornerstone of public health, significantly safeguarding children's health. Despite the imperative of achieving extensive COVID-19 vaccine coverage, vaccine hesitancy poses a major challenge. OBJECTIVE: This review's aim is to analyze parental COVID-19 vaccine acceptance and hesitancy during the COVID-19 pandemic and elucidate the factors that influenced their decisions. METHODS: A search of Medline (PubMed), Embase, and Psycinfo was conducted on February 1, 2022...
September 19, 2023: Vaccine
https://read.qxmd.com/read/37726181/a-measles-virus-based-vaccine-induces-robust-chikungunya-virus-specific-cd4-t-cell-responses-in-a-phase-ii-clinical-trial
#5
JOURNAL ARTICLE
Katharina S Schmitz, Anouskha D Comvalius, Nella J Nieuwkoop, Daryl Geers, Daniela Weiskopf, Katrin Ramsauer, Alessandro Sette, Roland Tschismarov, Rory D de Vries, Rik L de Swart
Chikungunya virus (CHIKV) is an alphavirus transmitted by mosquitos that causes a debilitating disease characterized by fever and long-lasting polyarthralgia. To date, no vaccine has been licensed, but multiple vaccine candidates are under evaluation in clinical trials. One of these vaccines is based on a measles virus vector encoding for the CHIKV structural genes C, E3, E2, 6K, and E1 (MV-CHIK), which proved safe in phase I and II clinical trials and elicited CHIKV-specific antibody responses in adult measles seropositive vaccine recipients...
September 17, 2023: Vaccine
https://read.qxmd.com/read/37726180/a-large-survey-on-covid-19-vaccination-in-patients-with-parkinson-s-disease-and-healthy-population
#6
JOURNAL ARTICLE
Chao Han, Zhen Zhen Zhao, Piu Chan, Fang Li, Chun Ling Chi, Xin Zhang, Yan Zhao, Jing Chen, Jing Hong Ma
BACKGROUND: A full rollout of COVID-19 vaccination offers the most promising prospect of bringing the pandemic to an end. This study aimed to compare the coverage, safety, and confidence of COVID-19 vaccination between patients with Parkinson's disease (PD) and healthy individuals so as to give suggestions for future immunization programs. METHODS: A web-based, nationwide, multicenter survey was carried out in China from 2021 to 2022. The age and sex-standardized vaccination rate was calculated...
September 17, 2023: Vaccine
https://read.qxmd.com/read/37726179/preclinical-evaluation-of-a-sars-cov-2-variant-b-1-351-based-candidate-dna-vaccine
#7
JOURNAL ARTICLE
Ria Lassaunière, Charlotta Polacek, Jeanette Linnea Tingstedt, Anders Fomsgaard
The SARS-CoV-2 pandemic revealed the critical shortfalls of global vaccine availability for emergent pathogens and the need for exploring additional vaccine platforms with rapid update potential in response to new variants. Thus, it remains essential, for the present evolving SARS-CoV-2/Covid-19 and future pandemics, to continuously develop and characterize new and different vaccine platforms. Here, we describe an expression-optimized DNA vaccine candidate based on the SARS-CoV-2 spike protein of the Beta variant (B...
September 17, 2023: Vaccine
https://read.qxmd.com/read/37718187/active-inoculation-with-an-inactivated-coxsackievirus-a2-vaccine-induces-neutralizing-antibodies-and-protects-mice-against-lethal-infection
#8
JOURNAL ARTICLE
Yuexia Wang, Wangquan Ji, Dong Li, Tiantian Sun, Peiyu Zhu, Junwei Li, Liang Zhang, Yu Zhang, Haiyan Yang, Shuaiyin Chen, Yuefei Jin, Guangcai Duan
Coxsackievirus A2 (CVA2) is one of the causative agents of hand-foot-and-mouth disease (HFMD), which poses a great challenge for global public health. However, presently, there are no available commercial vaccines or antivirals to prevent CVA2 infection. Here, we present an inactivated Vero cell-based whole CVA2 vaccine candidate and evaluate its safety and efficacy in this study. Neonatal BALB/c mice were vaccinated at 5 and 7 days old, respectively, and then challenged with either homologous or heterologous strain of CVA2 at a lethal dose at 10 days old...
September 15, 2023: Vaccine
https://read.qxmd.com/read/37718186/protocol-for-a-living-evidence-synthesis-on-variants-of-concern-and-covid-19-vaccine-effectiveness
#9
REVIEW
Nicole Shaver, Melanie Katz, Gideon Darko Asamoah, Lori-Ann Linkins, Wael Abdelkader, Andrew Beck, Alexandria Bennett, Sarah E Hughes, Maureen Smith, Mpho Begin, Doug Coyle, Thomas Piggott, Benjamin M Kagina, Vivian Welch, Caroline Colijn, David J D Earn, Khaled El Emam, Jane Heffernan, Sheila F O'Brien, Kumanan Wilson, Erin Collins, Tamara Navarro, Joseph Beyene, Isabelle Boutron, Dawn Bowdish, Curtis Cooper, Andrew Costa, Janet Curran, Lauren Griffith, Amy Hsu, Jeremy Grimshaw, Marc-André Langlois, Xiaoguang Li, Anne Pham-Huy, Parminder Raina, Michele Rubini, Lehana Thabane, Hui Wang, Lan Xu, Melissa Brouwers, Tanya Horsley, John Lavis, Alfonso Iorio, Julian Little
BACKGROUND: It is evident that COVID-19 will remain a public health concern in the coming years, largely driven by variants of concern (VOC). It is critical to continuously monitor vaccine effectiveness as new variants emerge and new vaccines and/or boosters are developed. Systematic surveillance of the scientific evidence base is necessary to inform public health action and identify key uncertainties. Evidence syntheses may also be used to populate models to fill in research gaps and help to prepare for future public health crises...
September 15, 2023: Vaccine
https://read.qxmd.com/read/37716830/covid-19-vaccine-effectiveness-against-hospitalizations-in-paraguay-may-2021-april-2022-a-test-negative-design
#10
JOURNAL ARTICLE
Sandra Irala, Sarah Hamid, Elena Penayo, Fabiana Michel, Paula Couto, Cynthia Vazquez, María José Ortega, Chavely Domínguez, Silvia Battaglia, Marta Von Horoch, Romeo Montoya, Guillermo Sequera, Francisco Nogareda
BACKGROUND: Vaccine effectiveness (VE) estimates vary by population characteristics and circulating variants. North America and Europe have generated many COVID-19 VE estimates but relied heavily on mRNA vaccines. Fewer estimates are available for non-mRNA vaccines and from Latin America. We aimed to estimate the effectiveness of several COVID-19 vaccines in preventing SARS-CoV-2-associated severe acute respiratory infection (SARI) in Paraguay from May 2021 to April 2022. METHODS: Using sentinel surveillance data from four hospitals in Paraguay, we conducted a test-negative case-control study to estimate COVID-19 vaccine effectiveness against SARI by vaccine type/brand and period of SARS-CoV-2 variant predominance (Gamma, Delta, Omicron)...
September 14, 2023: Vaccine
https://read.qxmd.com/read/37716829/evaluation-of-an-ielisa-for-detection-and-quantification-of-rabies-antibodies-in-domestic-dog-sera
#11
JOURNAL ARTICLE
Ahmed Lugelo, Katie Hampson, Lorraine M McElhinney, Felix Lankester
Many rabies endemic-countries have recognized rabies as a public health problem that can be eliminated. As a result, some countries have started implementing small-scale vaccination programs with the aim of scaling them up. Post-vaccination serological monitoring is crucial to assess the efficacy of these programs. The recommended serological tests, the rapid fluorescent focus inhibition test, and the fluorescent antibody virus neutralization (FAVN) are accurate; however, the procedures require considerable expertise and must be carried out in high containment facilities, which are often not available in rabies endemic countries...
September 14, 2023: Vaccine
https://read.qxmd.com/read/37716828/efficacy-and-immunogenicity-of-a-veterinary-vaccine-candidate-against-tick-borne-encephalitis-in-dogs
#12
JOURNAL ARTICLE
Jiri Salat, Milan Hunady, Pavel Svoboda, Lucie Strelcova, Petra Strakova, Andrea Fortova, Martin Palus, Daniel Ruzek
Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism...
September 14, 2023: Vaccine
https://read.qxmd.com/read/37714749/evolution-of-hiv-virulence-in-response-to-disease-modifying-vaccines-a-modeling-study
#13
JOURNAL ARTICLE
Molly C Reid, John E Mittler, James T Murphy, Sarah E Stansfield, Steven M Goodreau, Neil Abernethy, Joshua T Herbeck
Pathogens face a tradeoff with respect to virulence; while more virulent strains often have higher per-contact transmission rates, they are also more likely to kill their hosts earlier. Because virulence is a heritable trait, there is concern that a disease-modifying vaccine, which reduces the disease severity of an infected vaccinee without changing the underlying pathogen genotype, may result in the evolution of higher pathogen virulence. We explored the potential for such virulence evolution with a disease-modifying HIV-1 vaccine in an agent-based stochastic epidemic model of HIV in United States men who have sex with men (MSM)...
September 13, 2023: Vaccine
https://read.qxmd.com/read/37709591/vaccination-coverage-survey-of-children-aged-1-3-years-in-beijing-china-2005-2021
#14
JOURNAL ARTICLE
Wen-Yan Ji, Dong-Lei Liu, Rui Yu, Liang Miao, Qian-Li Yuan, Luo-Dan Suo, Jian-Ping Yu
BACKGROUND: The routine immunization program for children is a primary strategy and a core part of vaccination. Achieving and maintaining high level of vaccination coverage are important to reduce morbidity and mortality caused by vaccine-preventable diseases. In Beijing, annual coverage surveys have been conducted since 2005. It is necessary and possible to assess the level and trend of routine vaccination coverage of children in Beijing as well as the disruption of coronavirus disease 2019 (COVID-19) pandemic and provide the reference for the further improve the vaccination coverage...
September 12, 2023: Vaccine
https://read.qxmd.com/read/37704499/covid-19-vaccine-booster-doses-provide-increased-protection-against-covid-19-hospitalization-compared-with-previously-vaccinated-individuals-interim-findings-from-the-reforco-brazil-real-world-effectiveness-study-during-delta-and-omicron
#15
JOURNAL ARTICLE
Wilhelmine Meeraus, Anke L Stuurman, Ilgaz Durukal, Eduardo Conde-Sousa, Andrew Lee, André Santa Maria, Bárbara Emoingt Furtado, Mario Ouwens, Christen M Gray, Douglas Andreas Valverde, Hugo Gomes da Silva, Sylvia Taylor
BACKGROUND: Although COVID-19 booster vaccination is widely recommended, there is limited long-term, population-level, real-world evidence on the magnitude of improved protection against severe COVID-19 conferred by boosting with monovalent COVID-19 vaccines developed against ancestral SARS-CoV-2, especially in low- or middle-income countries. We present interim results from the first large-scale assessment of the relative vaccine effectiveness (rVE) of first and second booster doses against severe COVID-19 in a low-/middle-income country...
September 11, 2023: Vaccine
https://read.qxmd.com/read/37704498/prophylactic-hpv-vaccines-in-patients-with-hpv-associated-diseases-and-cancer
#16
REVIEW
Miriam Reuschenbach, John Doorbar, Marta Del Pino, Elmar A Joura, Caroline Walker, Rosybel Drury, Andreas Rauscher, Alfred J Saah
Individuals with human papillomavirus (HPV)-related disease remain at risk for subsequent HPV infection and related disease after treatment of specific lesions. Prophylactic HPV vaccines have shown benefits in preventing subsequent HPV-related disease when administered before or soon after treatment. Based on our understanding of the HPV life cycle and vaccine mechanism of action, prophylactic HPV vaccination is not expected to clear active persistent HPV infection or unresected HPV-associated dysplastic tissue remaining after surgery...
September 11, 2023: Vaccine
https://read.qxmd.com/read/37704497/integrative-transcriptomic-and-metabolomic-analysis-in-mice-reveals-the-mechanism-by-which-ginseng-stem-leaf-saponins-enhance-mucosal-immunity-induced-by-a-porcine-epidemic-diarrhea-virus-vaccination
#17
JOURNAL ARTICLE
Fei Su, Yin Xue, Shiyi Ye, Bin Yu, Junxing Li, Lihua Xu, Xiufang Yuan
Porcine epidemic diarrhea virus (PEDV) is a main cause of severe enteric disease in piglets, leading to millions of dollars lost annually in the global pig industry. Parenteral vaccination is limited in generating sufficient mucosal immunity, which is crucial for early defense against PEDV. Here, we orally administered ginseng stem-leaf saponins (GSLS) to mice before parenteral vaccination and found that GSLS significantly enhanced the phagocytosis of dendritic cells, promoted the activities of CD4+ T cells and increased PEDV-specific IgA antibodies in the intestinal mucosa...
September 11, 2023: Vaccine
https://read.qxmd.com/read/37699784/an-overview-of-protein-based-sars-cov-2-vaccines
#18
REVIEW
Yogesh R Suryawanshi
SARS-CoV-2 resulted in the COVID-19 pandemic which, to date, has resulted in an estimated loss of over 15 million human lives globally and continues to have negative social, and economic implications worldwide. Vaccine platforms that can be quickly updated to counter newly emerging SARS-CoV-2 variants are critical in combating the COVID-19 pandemic. Messenger RNA-based SARS-CoV-2 vaccines can be easily updated and have shown superior efficacy over other vaccine types, yet their high cost, reactogenicity, and stringent need for ultracold storage limit their accessibility...
September 10, 2023: Vaccine
https://read.qxmd.com/read/37699783/meeting-report-towards-better-risk-stratification-prevention-and-therapy-of-invasive-gbs-disease-espid-research-meeting-may-2022
#19
Linde Snoek, Konstantinos Karampatsas, Merijn W Bijlsma, Philipp Henneke, Elita Jauneikaite, Uzma B Khan, Ruth N Zadoks, Kirsty Le Doare
The European Society of Pediatric Infectious Diseases (ESPID) hosted the third Group B Streptococcus (GBS) Research Session in Athens on 11th May 2022, providing researchers and clinicians from around the world an opportunity to share and discuss recent advances in GBS pathophysiology, molecular and genetic epidemiology and how these new insights can help in improving prevention and control of early- and late-onset GBS disease. The meeting provided a state-of-the-art overview of the existing GBS prevention strategies and their limitations, and an opportunity to share the latest research findings...
September 10, 2023: Vaccine
https://read.qxmd.com/read/37699782/genomic-associations-with-antibody-response-to-an-oral-cholera-vaccine
#20
JOURNAL ARTICLE
Vijay Laxmi Roy, Partha P Majumder
Oral cholera vaccine is one of the key interventions used in our fight to end the longest pandemic of our time, cholera. The immune response conferred by the currently available cholera vaccines, as measured by serum antibody levels, is variable amongst its recipients. We undertook a genome wide association study (GWAS) on antibody response to the cholera vaccine; globally, the first GWAS on cholera vaccine response. We identified three clusters of bi-allelic SNPs, in high within-cluster linkage disequilibrium that were moderately (p < 5 × 10-6 ) associated with antibody response to the cholera vaccine and mapped to chromosomal regions 4p14, 4p16...
September 10, 2023: Vaccine
journal
journal
28816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.